Literature DB >> 20978595

Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery.

C Liesting1, F Z Ramjankhan, L A van Herwerden, M J M Kofflard.   

Abstract

Primary cardiac tumours are rare when compared with metastatic involvement. The majority of primary cardiac tumours are benign and in adults the majority of these masses are myxomas. The treatment is surgical removal because of the risk of embolisation and/or cardiovascular complications. We describe a female presenting with systemic embolisation and recurrence of cardiac myxoma after surgery. Recurrence of myxoma is rare after surgery in case of solitary tumours but more frequent in patients with familial myxomas in association with the Carney complex. Genetic analysis revealed a mutation in the PRKAR1A gene that has never been described before. (Neth Heart J 2010;18:499502.).

Entities:  

Keywords:  Carney Complex; Embolism; Interleukin; Myxoma; Recurrence

Year:  2010        PMID: 20978595      PMCID: PMC2954303          DOI: 10.1007/BF03091822

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  15 in total

1.  Cardiac myxomas: 24 years of experience in 49 patients.

Authors:  I M Keeling; P Oberwalder; M Anelli-Monti; H Schuchlenz; U Demel; G P Tilz; P Rehak; B Rigler
Journal:  Eur J Cardiothorac Surg       Date:  2002-12       Impact factor: 4.191

Review 2.  Growth rate of left atrial myxoma.

Authors:  S Malekzadeh; W C Roberts
Journal:  Am J Cardiol       Date:  1989-11-01       Impact factor: 2.778

3.  Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery.

Authors:  C Liesting; F Z Ramjankhan; L A van Herwerden; M J M Kofflard
Journal:  Neth Heart J       Date:  2010-10       Impact factor: 2.380

Review 4.  Cardiac tumours: diagnosis and management.

Authors:  Jagdish Butany; Vidhya Nair; Ather Naseemuddin; Girish M Nair; Charles Catton; Teri Yau
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

5.  Primary cardiac tumors: early and late results of surgical treatment in 91 patients.

Authors:  P Centofanti; E Di Rosa; L Deorsola; G M Dato; F Patanè; M La Torre; L Barbato; A Verzini; G Fortunato; M di Summa
Journal:  Ann Thorac Surg       Date:  1999-10       Impact factor: 4.330

6.  Cardiac myxomas: clinical and echocardiographic profile.

Authors:  K C Goswami; S Shrivastava; V K Bahl; A Saxena; S C Manchanda; H S Wasir
Journal:  Int J Cardiol       Date:  1998-02-28       Impact factor: 4.164

Review 7.  Cardiac myxomas.

Authors:  K Reynen
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells.

Authors:  Hironosuke Sakamoto; Tetsuo Sakamaki; Tsugiyasu Kanda; Yoko Tsuchiya; Mahito Sato; Hiroko Sato; Yuko Oyama; Yoshie Sawada; Jun-ichi Tamura; Ryozo Nagai; Masahiko Kurabayashi
Journal:  Circ J       Date:  2004-05       Impact factor: 2.993

9.  Multiple recurrences of nonfamilial cardiac myxomas: a report of two cases.

Authors:  Cesar Mendoza; Erik Bernstein; Alexandre Ferreira
Journal:  Tex Heart Inst J       Date:  2007

Review 10.  Four cardiac myxomas diagnosed three times in one patient.

Authors:  K Hermans; W Jaarsma; H W M Plokker; M J M Cramer; W J Morshuis
Journal:  Eur J Echocardiogr       Date:  2003-12
View more
  3 in total

1.  Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery.

Authors:  C Liesting; F Z Ramjankhan; L A van Herwerden; M J M Kofflard
Journal:  Neth Heart J       Date:  2010-10       Impact factor: 2.380

2.  Anesthetic experiences of myxoma removal surgery in two patients with Carney complex -A report of two cases-.

Authors:  Young Mi Kang; Yoon Hee Kim
Journal:  Korean J Anesthesiol       Date:  2011-12-20

3.  Cerebral aneurysms one year after resection of a cardiac myxoma.

Authors:  A W G J Oomen; S H H Kuijpers
Journal:  Neth Heart J       Date:  2013-06       Impact factor: 2.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.